Table A.1: Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	Center name, if applicable
Aller, Stephen G	Cystic Fibrosis Foundation ALLER16G0	Confirmation-Dependent Trapping and Small Molecule Click Mapping of CFTR	11/01/2016 – 10/31/2018	100,000	
Aller, Stephen G	Cystic Fibrosis Foundation ALLER16P0	Structure, Mechanisms and Function of CFTR	09/01/2016 – 08/31/2018	125,000	
Antony, Veena B	Cystic Fibrosis Foundation CC032-13AD	UAB Cystic Fibrosis Center for Care, Teaching, and Research (Adult)	7/1/2016 - 06/30/2019	115,430	
Bedwell, David M	National Institute of Neurological Disorders and Stroke/NIH/DHHS R21NS090928	New Nonsense Suppression Drugs to Treat MPS I[A]	9/1/2014 - 08/31/2017	250,000	
Bedwell, David M	CFF SOUTHERN RESEARCH INSTITUTE	The Identification of New Treatments for Cystic Fibrosis Caused by Premature Termination Codons-Bedwell Subcontract	8/14/2015 - 8/13/2020	251,394	
Bedwell, David M	University of Pennsylvania MPSI-16-002-01	Identification of Drugs to Treat MPS-IH Caused by Nonsense Mutations	5/1/2017 - 4/30/2018	150,000	
Bevensee, Mark Oliver	American Heart Association (Southeast Affiliate) 14GRNT20490031	Molecular Physiology of Na/Bicarbonate Cotransporters[B]	7/1/2014 - 06/30/2017	165,000	CDC
Birket, Susan Elizabeth	National Heart, Lung, and Blood Institute/NIH/DHHS K08HL131867	The Mechanisms Underlying Abnormal Mucus and its Clearance in the Cystic Fibrosis Rat	2/1/2017 - 01/31/2022	108,385	
Birket, Susan Elizabeth	Gilead Sciences BIRKET	The Mucus Clearance Defect Precedes Pseudomonas Aeruginosa Infection in the Cystic Fibrosis Rat	1/2/2017 - 12/31/2018	130,000	
Blalock, J Edwin	National Heart, Lung, and Blood Institute/NIH/DHHS R01HL126596	Genetics of Smoke-Altered LTA4H in COPD[C]	6/1/2015 - 05/31/2019	308,072	
Blalock, J Edwin	National Heart, Lung, and Blood Institute/NIH/DHHS R35HL135710	A Novel Exosomal Inflammatory Pathway[D]	1/18/2017 - 12/31/2023	600,000	
Casazza, Krista R.	Health Resources and Services Administration/DHHS 5T79MC00011-24-00	Leadership Education Excellence in Pediatric Nutrition	7/1/2014 - 6/30/2017	163,852	
Cho, Do Yeon	BIONORICA	Sinupret Treatment of Chronic Rhinosinusitis in a Preclinical Model	3/2/2017 - 3/1/2019	48,836	
Cho, Do Yeon	INTERSECT ENT, INC.	RESOLVE II Study: A Clinical Evaluation of the Safety and Efficacy of the Steroid-Releasing S8 Sinus Implant in Chronic Sinusitis Patients with Recurrent Sinus Obstruction	1/4/2016 - 01/03/2018	42,739	
Cho, Do Yeon	John Kirklin Research Award UAB Internal Grant N/A	CFTR defect in Rabbit Model of Sinusitis	02/01/2015 - 07/31/2017	25,000	
Collawn, James F	VETERANS ADMINISTRATION	VA IPA for Jim Collawn - Pathophysiology of Extracellular Matrix and Desmin Breakdown in Volume Overload (VO) Heart[E]	10/01/2016 - 09/30/2020	150,000	

Table A.1: Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	Center name, if applicable
Dransfield, Mark T	COPD FOUNDATION	Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)[F]	8/1/16 – 7/31/18	33,201	
Dransfield, Mark T	NIH Johns Hopkins University 2002831849 R01HL125169	Mucus Microstructure and Osmotic Pressure: Biomarkers for CB in COPD[G]	6/1/2015 - 05/31/2017	3,237	
Dransfield, Mark T	NIH NATIONAL JEWISH MEDICAL RESEARCH CENTER 24021306 R01HL089897	Genetic Epidemiology of COPD[H]	8/1/2013 - 07/31/2017	76,133	
Gaggar, Amit	Gilead Sciences	Matrix Metalloprotease-9 Profiles in CF and COPD	11/6/2015 - 11/05/2017	151,222	
Gaggar, Amit	Gilead Sciences	A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects with Cystic Fibrosis	2/22/2017 - 02/21/2019	35,045	
Guimbellot, Jennifer Susan	KAUL PEDIATRIC RESEARCH INSTITUTE	Development of Personalized Approaches to CFTR Modulator Efficacy	2/1/2016 - 01/31/2018	30,000	
Guimbellot, Jennifer Susan	Cystic Fibrosis Foundation N/A	Novel Approaches to CFTR Modulator Mechanism in Cystic Fibrosis	4/1/2017 - 3/31/20	390,000	
Gutierrez, Hector H	ALABAMA DEPARTMENT OF PUBLIC HEALTH C70115019	Cystic Fibrosis Screening for Newborn Infants	10/1/2016 - 09/30/2017	38,000	
Gutierrez, Hector H	CFF CHILDREN'S HOSPITAL & REGIONAL MEDICAL CENTER 10910SUB	The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with	4/1/2009 - 03/31/2019	6,666	
Gutierrez, Hector H	Cystic Fibrosis Foundation CMHC032-15	Implementation of the Depression and Anxiety Guideline: Award for a Mental Health Coordinator	1/1/2016 - 12/31/2018	50,101	
Gutierrez, Hector H	TLOAF University of Wisconsin-Madison 596K260	A Multi-Center Study of a New Method of Sweat Testing: The CF Quantum Sweat Test	1/1/2015 - 12/31/2017	20,000	
Harris, William Thomas	VERTEX PHARMACEUTICALS, INC.	A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation	9/9/2015 - 08/31/2017	25,375	
Harris, William Thomas	VERTEX PHARMACEUTICALS, INC.	A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-Term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation	9/9/2015 - 08/31/2017	57,019	
Harris, William Thomas	Cystic Fibrosis Foundation N/A	MiR-145 Mediated TGF-Beta Pathobiology in CF	4/1/2017 - 3/31/19	200,000	
Harris, William Thomas	VERTEX PHARMACEUTICALS, INC.	A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects with Cystic Fibrosis who are Less than 24 Months of Age at Treatment Initiation and have a CFTR Gating Mutation	4/27/2017 - 04/23/2018	35,493	

Table A.1: Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	Center name, if applicable
Harrod, Kevin	National Institute of Allergy and Infectious Diseases/NIH/DHHS R01AI111475	Targeting MMP9 to Improve Outcomes in Serious Influenza Infections	4/1/2014 - 03/31/2019	801,129	
Hartman, John L.	Cystic Fibrosis Foundation HARTMA15G0	Ribosomal Perturbation to Increase Functional Expression of F508del-CFTR	11/1/2016 - 10/31/2017	100,000	NORC, CDC
Hartman, John L.	Cystic Fibrosis Foundation HARTMA16G0	Genetic Analysis of X-mutation Read Through: Targets and Mechanisms	11/1/2016 - 10/31/2018	100,000	NORC, CDC
Hartman, John L.	National Institute on Aging/NIH/DHHS R01AG043076	Constructing Gene-Regulatory Networks to Reveal the Metabolic Basis of Lifespan in Yeast[I]	6/1/2012 - 05/31/2017	288,761	NORC, CDC
Hoover, Wynton C.	CFF SEATTLE CHILDREN'S RESEARCH INSTITUTE 10947SUB HOEFMA14A0	Prevalence and Significance of Staphylococcus Aureus Small–Colony Variants	4/1/2014 - 03/31/2018	27,956	
Hoover, Wynton C.	CFF SEATTLE CHILDREN'S RESEARCH INSTITUTE 11231SUB	Saline Hypertonic in Preschoolers (SHIP)	6/19/2015 - 06/18/2017	16,286	
Kappes, John C	Cystic Fibrosis Foundation KAPPES16XX0	Stabilized CFTR for Elucidating Biophysical & Structural Characteristics	9/1/2016 - 08/31/2018	166,321	
Keeling, Kim M	Cystic Fibrosis Foundation KEELIN15XX0	Increasing CFTR Expression by NMD Attenuation	11/1/2015 - 10/31/2017	150,000	
Keeling, Kim M	ELOXX PHARMACEUTICALS	Effect of Eloxx Compounds on a-L-iduronidase Activity in Cell and Animal Models[J]	9/14/2016 - 09/13/2018	182,953	
Keeling, Kim M	ELOXX PHARMACEUTICALS	The Effect of Aldurazyme Treatment in W402X Mice for an MPS I-H Indication[J]	9/14/2016 - 09/13/2018	36,931	
Keeling, Kim M	NIH - OFFICE OF THE DIRECTOR R21OD019922	Investigating the Effects of Reducing Nonsense-Mediated mRNA Decay Efficiency[J]	4/1/2016 - 03/31/2018	112,500	
Kirk, Kevin	Cystic Fibrosis Foundation KIRK16G0	The Tetrahelix Bundle in CFTR Gating: CF Mutations and Potentiator Rescue	11/01/2016 - 10/31/2018	108,000	
Kong, Michele	CHILDREN'S HOSPITAL (BOSTON)	Genetic Epidemiology and Immune Response to Life-Threatening Influenza Infection in Children and Yound Adults (PICFluv)[K]	8/19/2016 - 08/18/2020	10,000	
Kong, Michele	National Heart, Lung, and Blood Institute/NIH/DHHS K08HL119359	Matrix Metalloproteinase Driven Lung Inflammation in RSV Disease[L]	5/1/2014 - 04/30/2019	147,625	
Krick, Stefanie	Flight Attendant Medical Research Institute	The Role of Fibrosis Growth Factor Receptor Signaling and Inflammation in Chronic Bronchitis[M]	7/1/2016 - 06/30/2018	53,427	
Krick, Stefanie	Cystic Fibrosis Foundation KRICK16I	The Role of FGF Receptor Signaling in Cystic Fibrosis	4/1/2016 - 3/31/18	27,219	
Lal, Charitharth Vivek	American Heart Association 17SDG32720009 17SDG32720009	The Role of Pulmonary Microbiome Induced Ac-PGP in Bronchopulmonary Dysplasia and Associated Pulmonary Hypertension[N]	1/1/2017 - 12/31/2019	77,000	
Lal, Charitharth Vivek	KAUL PEDIATRIC RESEARCH INSTITUTE	The Role of Microbiome Induced Ac-PGP in Bronchopulmonary Dysplasia[N]	2/1/2017 - 01/31/2019	30,000	
Liu, Gang	National Heart, Lung, and Blood Institute/NIH/DHHS R35HL135830	Program on Cellular Metabolism and Lung Fibrosis[O]	1/1/2017 - 12/31/2023	500,000	
Lowman, John D.	CFF University of Pittsburgh 0046624(710986-1) ORENST14KO	Effects of a 6-Month Partially Supervised Conditioning Program in CF: an International Multi-Center Randomized Controlled Trial.	11/1/2014 - 10/31/2017	68,187	
Matalon, Sadis	National Institute of Environmental Health Sciences/NIH/DHHS U01ES026458	Bromine Inhalation Induced Lung Injury: Novel Mechanisms and Treatment Strategies[P]	9/1/15 – 8/31/20	536,464	
Matalon, Sadis	National Institute of Neurological Disorders and Stroke/NIH/DHHS U01ES027697	CIALIS® Reverses Halogen Induced Injury to Pregnant Animals and Their Offspring[Q]	9/30/2016 - 07/31/2021	540,143	

Table A.1: Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	Center name, if applicable
Raju, S.Vamsee	CELGENE CORPORATION	Evaluation of Apremilast for the Treatment of Cystic Fibrosis Patients with DF508 Mutation	2/14/2017 - 02/13/2018	105,000	
Raju, S.Vamsee	Flight Attendant Medical Research Institute	CFTR, A Novel Drug Target for COPD	7/1/2014 - 6/30/2017	100,000	
Rowe, Steven M	Bayer HealthCare	A Multi-Center, Randomized , Double-Blind, Placebo-Controlled Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult DF508 Homozygous Cystic Fibrosis Patients ("Study")	11/3/2016 - 11/02/2017	19,200	
Rowe, Steven M	NIH CFD RESEARCH CORPORATION 20160244 R34HL134056	A Predictive In Vitro Model for Screening Personalized Responses to CFTR-Directed Therapeutics	8/15/2016 - 07/31/2017	68,027	
Rowe, Steven M	Cystic Fibrosis Foundation GARCIA16B0	Effect of PAAG Treatment on CF Related Pseudomonas Infected Respiratory Epithelium	7/1/2016 - 06/30/2017	68,500	
Rowe, Steven M	Cystic Fibrosis Foundation ROWE14Y4	Additional Research Coordinator (ARC) Award	12/1/2016 - 11/30/2017	28,439	
Rowe, Steven M	Cystic Fibrosis Foundation ROWE16XX3	Brevenal Effect on Mucociliary Clearance for Treatment of CF Mucus	9/1/2016 - 8/31/2017	61,566	
Rowe, Steven M	Cystic Fibrosis Foundation ROWE17XX2	Evaluation of Arina-1 for the Treatment of Cystic Fibrosis Lung Disease	2/1/2017 - 01/31/2018	89,499	
Rowe, Steven M	ELOXX PHARMACEUTICALS	Evaluation of NB124 for the Treatment of Nonsense Mutation Cystic Fibrosis	2/8/2017 - 02/07/2018	41,323	
Rowe, Steven M	GALAPAGOS NV.	Evaluation of Potentiators on FTR-CFTR Stopcodon Mutants in TECC and/or Ussing Chamber	9/25/2016 - 02/07/2018	10,658	
Rowe, Steven M	GALAPAGOS NV.	Evaluation of Putative Abb Vie/Galapagos CFTR Potentiators in a Ferret Model of COPD	10/25/2016 - 10/24/2017	96,659	
Rowe, Steven M	GALAPAGOS NV.	Evaluation of Potentiators on HBE-G542X Epithelial Cells in TECC and/or Ussing Chamber	12/17/2016 - 12/16/2017	5,067	
Rowe, Steven M	IONIS PHARMACEUTICALS, INC.	In Vivo Evaluation of Antisense Oligonucleotide Technology in Treating Cystic Fibrosis Lung Disease	8/18/2016 - 08/17/2017	81,500	
Rowe, Steven M/Lin, Vivian	National Heart, Lung, and Blood Institute/NIH/DHHS F31HL134225	The Mechanism of Tobacco-Induced Decrements in Mucociliary Clearance	9/30/2016 - 09/29/2019	34,148	
Rowe, Steven M	National Heart, Lung, and Blood Institute/NIH/DHHS R01HL116213	Functional Anatomic Imaging of CF Patients with Early Lung Disease Using microOCT	7/1/2012 - 06/30/2017	250,000	
Rowe, Steven M	National Heart, Lung, and Blood Institute/NIH/DHHS R34HL127166	A Pilot Study of the Effect of the CFTR Potentiator Ivacaftor in COPD (P-Topic)	6/1/2015 - 05/31/2018	225,000	
Rowe, Steven M	National Heart, Lung, and Blood Institute/NIH/DHHS R35HL135816	Translational Program in CFTR-Related Airway Diseases	1/15/2017 - 12/31/2023	685,177	
Rowe, Steven M	NIH PROGENRA, INC. RHL130207A R41HL130207	In Vitro Human Model for Individualized Response to CFTR Modulators	9/6/2016 - 08/31/2017	65,487	
Rowe, Steven M	PTC THERAPEUTICS, INC.	An Open-Label Safety and Efficacy Study for Patients with Nonsense Mutation Cystic Fibrosis previously Treated with Ataluren (PTC124®)	6/26/2014 - 06/25/2017	11,575	
Rowe, Steven M	PTC THERAPEUTICS, INC.	A Phase 3 Extension Study of Ataluren (PTC124®) In Patients with Nonsense Mutation Cystic Fibrosis	11/13/2014 - 11/12/2017	18,197	
Rowe, Steven M	PULMOTECT	In Vivo Evaluation of PUL-042 in Ferrets	10/5/2016 - 10/04/2017	10,000	
Rowe, Steven M	RANA THERAPEUTICS	In Vivo and Ex Vivo Evaluation of Nebulized Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mRNA Replacement Therapy in Treating Cystic Fibrosis Lung Disease	4/25/2017 - 04/24/2018	62,050	

Table A.1: Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	Center name, if applicable
Rowe, Steven M	CFF SEATTLE CHILDREN'S HOSPITAL 11162SUB	A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT) ("Clinical Study")	7/1/2016 - 06/30/2017	11,177	
Rowe, Steven M	CFF SEATTLE CHILDREN'S RESEARCH INSTITUTE 10843SUB	G551D Observational Study-Expanded to Additional Genotypes and Extended for Long Term Follow-Up (GOAL-e2)	1/1/2017 - 12/31/2017	7,241	
Rowe, Steven M	CFF SOUTHERN RESEARCH INSTITUTE	The Identification of New Treatments for Cystic Fibrosis Caused by Premature Termination Codons	8/14/2015 - 08/13/2020	250,000	
Rowe, Steven M	CFF SYNEDGEN, INC	Prevention and Treatment of GI Obstruction Syndromes in Cystic Fibrosis	1/1/2017 - 12/31/2017	0	
Rowe, Steven M	UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION	Micro-CT Scanner for Ultra-High Resolution Live Imaging of Large and Small Animals	11/1/2016 - 10/31/2017	79,900	
Rowe, Steven M	University of Pennsylvania MDBR-16-120-CF1282x	An Open Label N of 1 Study to Evaluate the Safety and Efficacy of Long-Term Treatment with Ivacaftor in Combination with ALTALUREN (PTCD124) In Subjects with Nonsense Mutation Cystic Fibrosis	1/1/2017 - 12/31/2017	51,500	
Rowe, Steven M	VERTEX PHARMACEUTICALS, INC.	A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Exploratory Study to Evaluate Effects of VX-661 in Combination With Ivacaftor on Lung and Extrapulmonary Systems in Subjects Aged 18 Years and Older With Cystic Fibrosis, Homozygous for the	9/4/2014 - 07/03/2017	107,407	
Rowe, Steven M	VERTEX PHARMACEUTICALS, INC.	A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Exploratory Study to Evaluate Effects of VX-661 in Combination With Ivacaftor on Lung and Extrapulmonary Systems in Subjects Aged 18 Years and Older With Cystic Fibrosis, Homozygous for the	8/4/2016 - 07/03/2017	62,615	
Rowe, Steven M	VERTEX PHARMACEUTICALS, INC.	A Phase 4, 2 Part Exploratory Study to Assess the Feasibility of Using Micro Optical Coherence Tomography (uOCT) and to Evaluate The Effect of Lumacaftor in Combination With Ivacaftor on the Nasal Epithelium Using uOCT in Subjects With CF Who Are Homozygous for the	8/15/2016 - 08/14/2017	1,371,740	
Rowe, Steven M	VERTEX PHARMACEUTICALS, INC.	A Phase 3, Open-Label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment with VX-661 in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis, Homozygous or Heterozygous for	10/5/2016 - 10/04/2017	0	
Rowe, Steven M	VERTEX PHARMACEUTICALS, INC.	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and With a Second CFTR Mutation That Is Not Likely to Respond to VX-661 and/or Ivacaftor	10/15/2016 - 06/14/2017	0	
Rowe, Steven M	VERTEX PHARMACEUTICALS, INC.	NPD Reading Services for Project Entitled " A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects 6 Years of Age and Older with Cystic Fibrosis and a	10/30/2016 - 09/30/2017	2,633	
Rowe, Steven M	VERTEX PHARMACEUTICALS, INC.	A Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The Topic Trial)	11/29/2016 - 11/28/2017	0	

Table A.1: Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	Center name, if applicable
Rowe, Steven M	VERTEX PHARMACEUTICALS, INC.	A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a Second CFTR Allele With a Gating Defect That is Clinically Demonstrated to be Ivacaftor	2/5/2017 - 08/04/2017	0	
Garcia, Bryan	Cystic Fibrosis Foundation N/A	Developing Innovative Gastroenterology Specialty Training (DIGEST)Programs	6/15/2016 - 7/31/19	30,000	
Rowe, Steven M	Cystic Fibrosis Foundation N/A	Mechanisms of and Therapies for Abnormal Mucus Adhesion and Clearance in CF	8/1/2016 - 7/31/17	300,000	
Rowe, Steven M	Cystic Fibrosis Foundation ROWE17XX1	Core Center for Measurements of Mucus and Mucociliary Clearance	8/1/2016 - 8/31/17	400,000	
Rowe, Steven M	MASSACHUSETTS GENERAL HOSPITAL N/A	Development of Optical Coherence Tomography for Measures of Mucociliary Clearance	8/1/2016 - 7/31/17	27,778	
Rowe, Steven M	NIH - National Institutes of Health/DHHS N/A	The Mechanism of Tobacco-Induced Decrements in Mucociliary Clearance	4/1/2017 - 03/31/19	73,338	
Rowe, Steven M	UNIVERSITY OF COLORADO DENVER - NEW N/A	Idiopathic Pulmonary Fibrosis, A Disease Initiated by Mucociliary Dysfunction	7/1/2017 - 06/30/21	148,692	
Rowe, Steven M	UNIVERSITY OF COLORADO DENVER - NEW N/A	Idiopathic Pulmonary Fibrosis, a Disease Initiated by Mucociliary Dysfunction	12/1/2017 - 11/30/22	164,838	
Solomon, George	Cystic Fibrosis Foundation SOLOMO16A0	Rare Cell Collection Protocol for CF Patients with Rare CFTR Mutations (RACE)	11/1/2016 - 10/31/2017	18,153	
Solomon, George	PARION SCIENCES, INC.	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation in Subjects with Primary Ciliary Dyskinesia	10/20/2016 - 10/19/2017	30,558	
Solomon, George	NIH SEATTLE CHILDREN'S HOSPITAL 11148SUB UM1UL119973	Proof of Principal Evaluation of IV Gallium Nitrate (Ganite) in Patients with Cystic Fibrosis	7/1/2016 - 06/30/2017	0	
Solomon, George	CFF SEATTLE CHILDREN'S HOSPITAL 1138SUB	Standardized Treatment of Pulmonary Exacerbations II	1/1/2017 - 12/31/2017	22,570	
Solomon, George	VERTEX PHARMACEUTICALS, INC.	NPD Reading Services for Project Entitled "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Firocaftor in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis	1/1/2017 - 12/31/2017	19,150	
Solomon, George	VERTEX PHARMACEUTICALS, INC.	A Phase 2, Randomized, Double-Blind, Controlled Study to Evaluate the Safety of VX-152 Combination Therapy in Adults with Cystic Fibrosis	1/12/2017 - 1/11/2018	65,761	
Stalvey, Michael S.	VERSARTIS INC.	An Open-Label, Long-Term Safety Study of A Long-Acting Human Growth Hormone Somavaratan (VRS-317) in Children with Growth Hormone Deficiency	12/1/2016 - 11/30/2017	89,988	
Steele, Claude Henry	Cystic Fibrosis Foundation STEELE16I0	The CXCL 10/CXCR3 Axis in CF-Related Fungal Exposure	11/1/2016 - 10/31/2018	50,000	
Steele, Claude Henry	National Heart, Lung, and Blood Institute/NIH/DHHS R01HL122436	Immunopathogenesis in Fungal Asthma[R]	12/1/2014 - 11/30/2019	301,929	
Steele, Claude Henry	National Heart, Lung, and Blood Institute/NIH/DHHS R01HL126211	Biology of Innate IL-22 During Lung Fungal Infection[S]	1/1/2016 - 12/31/2020	250,000	
Swords, William E.	National Institute on Deafness & Other Communication Disorders/NIH/DHHS R01DC010451	Microbial Interactions in Otitis Media[T]	4/1/2016 - 3/31/2019	225,254	

Table A.1: Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	Center name, if applicable
Swords, William E.	RENOVION, INC.	Antibacterial Evaluation of Arina-1 for the Treatment of Cystic Fibrosis Lung Disease	8/18/2016 - 08/17/2018	19,500	
Thannickal, Victor John; Liu, Gang; Liu, Rui Ming, Antony, Veena	National Heart, Lung, and Blood Institute/NIH/DHHS P01	Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease[U]	8/1/2013 - 07/31/2018	467,000	
Thannickal, Victor; Locy, Morgan	National Heart, Lung, and Blood Institute/NIH/DHHS	Protein o, o'-Dityrosine Cross-Linking in Lung Injury and Wound Healing[V]	2/1/2016 - 01/31/2020	34,376	
Thannickal, Victor John	National Institute on Aging/NIH/DHHS	Myofibroblast Senescence in Pulmonary Fibrosis	6/1/2014 - 05/31/2019	225,000	
Virella-Lowell, Isabel	CELTAXSYS, INC.	A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic	2/5/2017 - 02/04/2018	0	
Virella-Lowell, Isabel	Cystic Fibrosis Foundation	TDN Additional Research Coordinator	1/1/2017 - 12/31/17	31,713	
Virella-Lowell, Isabel	Cystic Fibrosis Foundation	TDN PI Protected Effort	1/1/2017 - 12/31/2018	7,456	
Wells, James Michael	FOREST RESEARCH INSTITUTE, INC.	Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Aclidinium Bromide on Long-Term Cardiovascular Safety and COPD Exacerbations in Patients with	11/7/2016 - 11/06/2017	36,865	

Table A.1: Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	Center name, if applicable
Wells, James Michael	National Heart, Lung, and Blood Institute/NIH/DHHS K08HL122940	The Role of PGP in COPD-Associated Pulmonary Hypertension[X]	6/1/2014 - 05/31/2019	149,816	
Woodworth, Bradford A.	National Heart, Lung, and Blood Institute/NIH/DHHS R01HL122996	Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis	8/1/2016 - 05/31/2021	250,000	
Woodworth, Bradford A.	Stanford University	Use of Porcine Small Intestinal Submucosa (SIS) Graft to Aid in Nasal Septal Remucosalization and Tissue Healing in Patients Following Use of Nasoseptal Flap Elevation for Skull Base Surgery	4/3/2014 - 04/02/2018	0	
Yoder, Bradley K	Polycystic Kidney Disease Foundation 214g16a	Injury Response Mediated Pathogenesis in Ciliopathies[Z]	3/1/2016 - 02/28/2018	80,000	NORC, CDC
Yoder, Bradley K	NIH University of California, San Francisco 9864sc R01HD089918	Understanding Ciliary Functions in Mammalian Development[Y]	10/10/2016 - 11/30/2021	163,177	NORC, CDC
Zinn, Kurt R	NAVIDEA BIOPHARMACEUTICALS, INC	Molecular Imaging of M2-Polarized Macrophages in Autoimmune Disease[Z]	12/14/2015 - 12/13/2020	6,625	NORC, CDC
Zinn, Kurt R	UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION	Optical Imaging in Small Animal Models with the Lumina III System[AA]	11/1/2015 - 10/31/2017	51,219	NORC, CDC
Zinn, Kurt R	NIH University of Montana PG16-64514-02 U01NS092492	Molecular Imaging of Chemical Threats and Countermeasures[Z]	8/1/2016 - 07/31/2018	16,874	NORC, CDC

Table A.1: Current CF-Related Research Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	Center name, if applicable

A. Drugs identified that target CFTR nonsense suppressions are also being testing for MPS1. Similarly, new drugs discovered for MPS1 are shared with CF investigators.

B. Pathways sensitive to PH are also being translated to CF epithelia in pilot studies.

C. Genetic modulation of the LTA4 pathway is also relevant to extinguishing inflammation in CF. UAB is leading an international trial to inhibit LTA4 in CF.

D. Dr. Blalock is investigating exosomes as a delivery mechanism for generating PGP, a CF relevant inflammatory pathway.

E. The same pathways in volume overload are also being evaluated in the CF rat and CFTR's contribution to cardiomyopathy (submitted pilot).

F. The Spiromics database is being used to analyze the impact of acquired CFTR dysfunction.

G. The same mucus microstructure pathways evaluated here originated as an indicator of CF and acquired CFTR dysfunction.

H. Genetic analysis also includes the prevalence of CFTR mutations to confirm acquired CFTR dysfunction.

I. The networks included readouts of YOR1 activity, an oliomycin resistance gene now engineered to readout on F508del CFTR folding.

J. Suppression of nonsense mutation pathways and nonsense mediated decay are directly relevant to our CFTR nonsense mutation project.

K. Pathways surrounding influenza are directly relevant to CF exacerbations.

L. The MMP pathways investigated here were originally discovered in CF and the RSV driven pathophysiology are also relevant to mechanisms of CF exacerbations.

M. Fibrosis growth factor signaling includes ion transport relevant pathways, including the implications on acquired CFTR dysfunction.

N. The microbiome pathways in relationship to A_C-PGP signaling were proposed in a P30 pilot and initial studies have commenced in CF.

O. Altered cellular energetics are also being evaluated in the CF lung and may impact lung remodeling.

P. Epithelial dysfunction has been observed with bromine, including impacting ENaC and CFTR function.

Q. This project utilized pregnant rats prepared by the CF Center; Pups of pregnant animals also being assessed for CFTR abnormalities

R. Fungal asthma, including ABPA, is highly relevant to CF, and analysis includes CF specimen and CF registry data are included in the project.

S. IL-22 is highly active in ABPA, a complication of CF, and is directly relevant to CF fungal induced inflammation

T. Pathways involving microbial interaction are also being evaluated in CF (Pilot submitted) as well as chronic bronchitis in ferrets with acquired CFTR dysfunction.

U. NOX-4 relevant pathways for H2O2 production have been incorporated into the funded P30 Pilot Project by Dr. Thannickal. The clinical core (V. Antony) interacts with the CF Center P30 to efficiently process lung transplanted tissue, including controls.

V. Dihydrotyrosine cross linking is the same pathway being evaluated in the CF pilot project and refers to wound healing of the lung.

W. PGP was originally discovered as a CF relevant mechanism, and sweat testing was performed in these studies to assess repair of acquired CFTR dysfunction in parallel with effects on PGP.

X. M. Wells discovered Pulmonary hypertension is much more prevalent in CF than previously anticipated, and is evaluating whether PGP is part of that mechanism.

Y. Study of ciliopathies heavily utilized the CF Center Cores. Likewise, animal models developed by Dr. Yoder (PCD x CFTR KO mice) have been incorporated into CF projects.

Z. Molecular imaging techniques have included mucociliary clearance measures for CF.

AA. Molecular imaging techniques have included mucociliary clearance measures for CF; the CFRC contributed to the purchasing of the LuminaIII system for this and other applications.

Special Note: It should be noted that a number of awards are assigned to Dr. Rowe, which occurred as part of our stream-lined process to arrange research contracts with 3rd parties. This occurred in part due to the transition in PIs, and the fact that this process was new to the Center. In the future, we expect these to be assigned to the Core Director(s) directing the project (rather than all being assigned to a single PI).

Table A.2: Other Current Cystic Fibrosis-Related Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	DK Center name, if applicable
Barnes, Stephen	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS P30DK056336	UAB Nutrition Obesity Research Center - NORC Pilot and Feasibility Program[A]	06/01/2012 - 05/31/2017	157,485	Nutrition Obesity Res Ctr (NORC), Comprehensive Diabetes Center (CDC)
Barnes, Stephen	National Institute of General Medical Sciences/NIH/DHHS R25GM103798	UAB Metabolomics Workshop: From Design to Decision[B]	9/1/2012 - 08/31/2017	99,993	Nutrition Obesity Res Ctr (NORC), Comprehensive Diabetes Center (CDC)
Dransfield, Mark T	American Lung Association	Airways Clinical Research Center (ACRC)[C]	7/1/2016 – 6/30/2018	100,000	
Grizzle, William E	National Cancer Institute/NIH/DHHS UM1CA183728	Collaborative Human Tissue Network[D]	4/1/2014 - 03/31/2019	453,407	
Gutierrez, Hector H	Cystic Fibrosis Foundation CC032-16	UAB Cystic Fibrosis Center for Care, Teaching, and Research	7/1/2016 - 06/30/2018	179,200	
Hathorne, Heather Y	Cystic Fibrosis Foundation HATHOR14PF0	Success with Therapies Research Consortium	8/1/2014 - 07/31/2017	25,000	
Hoover, Wynton C.	Cystic Fibrosis Foundation CCPT032-16	Pediatric Physical Therapist Award	11/1/2016 - 10/31/2019	27,778	
Kesterson, Robert Allen	INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH - PUNE (IISER-PUNE)	Collaboration Agreement regarding Manufacture of Genetically modified Animals[E]	3/6/2017 - 03/05/2020	233,018	
Kimberly, Robert	National Institute for Health/National Center for Advancing Translational Sciences UL1TR001998	UAB Center for Clinical and Translational Science (CCTS)[F]	9/1/2015 - 8/31/2020	5,119,875	NORC, CDC
Lorenz, Robinna	National Institute of General Medical Sciences/NIH/DHHS T32GM008361	Medical Scientist Training Program	7/1/2015 - 6/30/2020	697,095	NORC, CDC
MacDougall, Mary J.	National Institute of Dental and Craniofacial Research/NIH/DHHS T90DE022736	Dental Academic Research Training Program[G]	7/1/2012 - 06/30/2022	452,758	

Table A.2: Other Current Cystic Fibrosis-Related Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	DK Center name, if applicable
Rowe, Steven M	Cystic Fibrosis Foundation ROWE14Y0	UAB Cystic Fibrosis Translational Development Center	1/1/2015 - 12/31/2019	201,350	
Rowe, Steven M	Cystic Fibrosis Foundation ROWE15R0	Research Development Program	7/1/2015 - 06/30/2019	525,000	
Steele, Claude Henry	National Heart, Lung, and Blood Institute/NIH/DHHST32HL134640	UAB Predoctoral Training Program in Lung Diseases	7/1/2016 - 6/30/21	988,910	
Thannickal, Victor John	National Heart, Lung, and Blood Institute/NIH/DHHS T32HL105346	Training Program in Lung Biology and Translational Medicine[H]	9/1/2015 - 08/31/2020	342,471	
Troxler, Brad	Health Resources and Services Administration/DHHS T32MC00001	Pediatric Pulmonary Center Training Award	7/1/2015 - 6/30/2020	314,815	
Yoder, Bradley K	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	Hepato/Renal Fibrocystic Diseases Core Center (UAB HRFDCC) - The Hepato/Renal Fibrocystic Diseases Engineered Models Resource[I]	7/1/2015 - 06/30/2020	709,178	NORC, CDC
Yoder, Bradley K	National Institute of General Medical Sciences/NIH/DHHS T32GM008111	Predoctoral Training in Cell and Molecular Biology[J]	7/1/2013 - 06/30/2018	267,544	NORC, CDC

A. The NORC P/F program has included CF related submissions, such as a project devveloped by Stalvey. NORC has also co-sponsored nutrition-oriented speakers with CFRC. We plan to co-submit RFAs for pilot studies in the future.

B. Multiple CF Investigators have used the metabolic workshop to train on CF relevant pathways.

C. The airways program has considerable interaction with CF.

D. The Collaborative Human Tissue Network includes resources for processing all CF lung transplant specimens.

E. This mechanism also supports production of CF mice, CF rats, and humanized CF rats.

F. The Child Health Research Unit houses the CF clinical research faciilties and is directed by Dr. Rowe and Dr. Reddy. This program also supports the Alabama Drug Discovery Alliance, which has been used as a HTS facility for CF applications.

G. Trainees in the Dental Program have included CF specific investigations into the origin of tooth dentition using the CF rat.

H. Multiple CF post-doctoral fellows, including some who have matriculated to junior faculty, have used this program.

I. Renal fibrocystic disease is governed by ciliary function and also CFTR specific ion transport. These pathways are incorporated in the project and proposed in a pilot.

J. CF Center graduate students are currently training with this mechanism.

Table A.3: Pending Cystic Fibrosis-Related Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	Center name, if applicable
Aller, Stephen G	NIH - National Institutes of Health/DHHS / N/A	X-Ray Crystal Structure of Human CTR1[A]	9/1/2017 - 8/31/22	2,706,258	
Antony, Veena B	Cystic Fibrosis Foundation N/A	Award for a Mental Health Coordinator	1/1/2017 - 12/31/19	150,000	
Antony, Veena B	Cystic Fibrosis FoundationCCPT250-16/JD #250 N/A	Physical Therapist - UAB Adult CF Clinic	1/1/2017 - 12/31/18	94,434	
Antony, Veena B	National Institute of Environmental Health Sciences/NIH/DHHSP42ES027723	Impact of Airborne Heavy Metals on Lung Disease and the Environment[B]	4/1/2017 - 3/31/22	8,375,000	
Antony, Veena B	National Institute of Environmental Health Sciences/NIH/DHHSR01ES028474	Environmental Exposure to Cadmium and the Development of COPD[B]	7/1/2017 - 6/30/22	1,982,225	
Barnes, Stephen	University of North Carolina at Charlotte N/A	Parameter-free Peak Detection Algorithm for Reducing False Positive/Negative Compound Identification from Raw Mass Spectrometry Metabolomics Data[C]	9/1/2017 - 8/31/18	18,466	Nutrition Obesity Res Ctr (NORC), Comprehensive Diabetes Center (CDC)
Bernard, Karen F.	American Heart Association N/A	Interaction Between Nox4 and Nrf2 in the Pathophysiology of Lung Fibrosis	1/1/2017 - 12/31/19	210,000	
Bernard, Karen F.	NIH - National Institutes of Health/DHHS N/A	Glutaminolysis in the Regulation of Fibroblast Activation and Lung Fibrosis	9/1/2017 - 8/31/22	1,449,170	
Birket, Susan Elizabeth	VERTEX PHARMACEUTICALS, INC. N/A	Ivacaftor for Correction of the Mucus Clearance Defect in a Humanized G551D Rat Model	1/1/2017 - 12/31/2019	0	
Cho, Do Yeon	CYSTIC FIBROSIS RESEARCH, INC. N/A	Controlled Delivery of Ciprofloxacin and Ivacaftor via Sinus Stent in Pseudomonas Rhinosinusitis	4/1/2017 - 3/31/20	134,114	
Cho, Do Yeon	AMERICAN RHINOLOGIC SOCIETY (ARS) N/A	Controlled Ciprofloxacin and Ivacaftor Delivery via Sinus Stent	7/1/2017 - 6/30/19	22,706	
Cho, Do Yeon	Sanofi US Services Inc N/A	A Randomized, 24-Week Treatment, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids	7/1/2017 - 6/30/19	160,120	
Dransfield, Mark T	American Lung Association N/A	Airways Clinical Research Centers (ACRC)	7/1/2017 - 6/30/18	100,000	
Dransfield, Mark T	NIH - National Institutes of Health/DHHS N/A	UAB Mentoring Program in COPD Patient Oriented Research	9/1/2017 - 8/31/21	435,550	
Dransfield, Mark T	Temple University N/A	Prospective Randomized Trial of Nocturnal Noninvasive Positive Pressure Ventilation on Time to Re-Hospitalization after COPD Hospitalization (RECOVER-COPD)	7/17/2017 - 6/30/24	454,814	
Dransfield, Mark T	University of California, San Francisco N/A	SPIROMICS II: Biological Underpinnings of COPD Heterogeneity and Progression	7/1/2017 - 6/30/22	476,854	
Gaggar, Amit	NIH - National Institutes of Health/DHHS N/A	A Novel Proteolytic System of Pulmonary Inflammation[D]	7/1/2017 - 6/30/22	1,250,000	
Harrod, Kevin	NIH - National Institutes of Health/DHHS N/A	Influenza Exacerbations in Chronic Bronchitis	9/1/2017 - 8/31/19	275,000	
Hartman, John L.	Emory University N/A	Ribosomal Perturbation as a Mechanism to Prevent Misfolding of CFTR	4/1/2017 - 3/31/22	622,028	NORC, CDC
Hartman, John L.	Emory University N/A	Ribosomal Perturbation as a Mechanism to Prevent Misfolding of CFTR	9/1/2017 - 8/31/22	798,635	NORC, CDC
Hartman, John L.	National Institute on Aging/NIH/DHHSR01AG056435	Discovery of Genetic and Metabolic Network Dynamics to Explain Complex Aging Phenotypes in Response to Gene and Nutrient Perturbations	7/1/2017 - 6/30/22	2,490,151	NORC, CDC

Table A.3: Pending Cystic Fibrosis-Related Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	Center name, if applicable
Hoover, Wynton C.	University of North Carolina at Chapel Hill N/A	Treatment Refractory Isolates during STaphylococcus Aureus Resistence - TRISTAR	4/1/2017 - 3/31/18	10,485	
Kesterson, Robert Allen	NIH - OFFICE OF THE DIRECTORR24OD022022	UAB Rat Ciliopathy Resource	4/1/2017 - 3/31/21	1,992,622	NORC, CDC
Kong, Michele	Gilead Sciences N/A	Treatment of RSV Murine Model with MMP-9 mAB and Non-Antibacterial Macrolide	2/1/2017 - 1/31/18	59,345	
Nahm, Moon	Jackson Laboratory N/A	Immunogenomics of Pneumococcal Vaccination[E]	12/1/2017 - 11/30/21	499,595	
Oates, Gabriela R.	American Thoracic Society N/A	Inequity Pathways in Chronic Obstructive Pulmonary Disease: Social Determinants of Adherence to Inhaled Medications	8/1/2017 - 7/31/18	24,990	
Rowe, Steven M	ARROWHEAD RESEARCH CORPORATION N/A	Evaluation of Nebulized Alpha ENaC RNAi Therapy in Treating Cystic Fibrosis Lung Disease	2/16/2017 - 2/15/18	164,100	
Solomon, George	ELECTROMED, INC. N/A	Assessment of Clinical Outcomes Following Smartvest Therapy	3/1/2017 - 2/28/18	29,059	
Solomon, George	Emory University N/A	Rare Mutations in Cystic Fibrosis: Overcoming Barriers to Personalized Medicine	9/1/2017 - 8/31/22	345,355	
Solomon, George	National Heart, Lung, and Blood Institute/NIH/DHHSK08HL138153	Functional Categorization of Ciliary Motion in PCD	6/1/2017 - 5/31/22	538,180	
Swords, William E.	Cystic Fibrosis Foundation N/A	Opportunistic Infections in Cystic Fibrosis	4/1/2017 - 3/31/19	200,000	
Swords, William E.	National Institute of Allergy and Infectious Diseases/NIH/DHHSR21AI133445	Dysbiotic Infections in Chronic Obstructive Pulmonary Disease	7/1/2017 - 6/30/19	275,000	
Swords, William E.	NIH - National Institutes of Health/DHHS N/A	Haemophilus Influenzae Quorum Signaling/Sensing	4/1/2018 - 3/31/23	1,250,000	
Swords, William E.	NIH - National Institutes of Health/DHHS N/A	Biofilm Communities in Otitis Media[F]	4/1/2018 - 3/31/23	1,250,000	
Thannickal, Victor John	National Heart, Lung, and Blood Institute/NIH/DHHSP01HL114470	Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease	8/1/2018 - 7/31/23	8,463,424	
Troxler, Robert Bradley	CINCINNATI CHILDREN'S HOSPITAL N/A	Flexible Lifestyles for Youth with CF: Pilot Behavioral Intervention Trial	9/1/2017 - 8/31/20	16,490	
Virella-Lowell, Isabel	GALAPAGOS NV. N/A	A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Multiple Doses of GLPG2222 in Subjects with Cystic Fibrosis who are Homozygous for the F508del Mutation	3/3/2017 - 3/2/18	0	

Table A.3: Pending Cystic Fibrosis-Related Grant Support

Principal Investigator [MPI or Co-Investigator]	Supporting Organization/ Grant Number	Title	Project Period	Annual Direct Costs	Identify other DK Center(s), if grant is included as part of its research base
Last Name, First Name	Complete number if none, then write N/A	Complete title as shown on the grant		Direct Cost $US	Center name, if applicable
Wells, James Michael	CHEST FOUNDATION N/A	PGP/AcPGP in Individuals at Risk for Acute Exacerbations of COPD[G]	9/15/2017 - 9/14/18	50,000	
Yoder, Bradley K	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHSF32DK113649	Dysregulated Crosstalk Between Ciliated Bile Duct Epithelial Cells and Immune Cells in Progression of Biliary Hyperplasia, Fibrosis, and Hepatorenal Fibrocystic Disease[H]	4/1/2017 - 3/31/19	114,120	NORC, CDC
Zhao, Rui	NIH - National Institutes of Health/DHHS N/A	Regulation of Pluripotent Stem Cell Differentiation by MicroRNA-Mediated Pathways	9/1/2017 - 8/31/22	1,444,755	

A. Dr. Aller is now investigating the same x-ray techniques for human CFTR, augmented by addition of stabilizing pharmaceuticals.

laready been prepared.

C. The mass spectroscopy techniques here are also being used to improve detection of post translational modifications of CFTR, and improves sensitivity for detecting acrolein and other constituents that cause acquired CFTR dysfunction.

D. This project includes CF as the primary model, and received a priority score (8%) in the funding range.

E. Dr. Nahm has postulated abnormal vaccination responses may also be prevalent in CF, and also be a target for anti-Pseudomonas intervention. Discussions regarding a CFRC-funded pilot are u

F. Pathways of microbial interaction in otitis media are also being evaluated in CF and chronic bronchitis ferrets with acquired CFTR dysfunction.

G. The PGP/Ac-PGP axis was discovered in CF and is also being evaluated as a marker of CF exacerbations. The banked specimens in the CF center will be used in this award.

H. Ciliated cell cross talk will attempt to use OCT imaging to discern mechanism and ciliary function, and is likely affected by abnormalities of mucus, such as CF, which will be tested with the CF/PCD crossed mice.